Equities research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.
Oragenics Stock Performance
OGEN stock opened at $0.40 on Thursday. The firm has a market cap of $1.79 million, a P/E ratio of -0.05 and a beta of 0.46. The firm’s fifty day moving average is $0.89 and its 200 day moving average is $1.24. Oragenics has a 52 week low of $0.38 and a 52 week high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.51) EPS for the quarter.
Institutional Trading of Oragenics
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- Stock Average Calculator
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Are Penny Stocks a Good Fit for Your Portfolio?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What is an Earnings Surprise?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.